Capricor announces positive six-month results from randomized phase I/II trial
Capricor nnounced positive top-line results from a safety and exploratory efficacy analysis of six-month data from the randomized 12-month Phase I/II HOPE Clinical Trial of CAP-1002 (allogeneic cardiosphere-derived cells), an investigational candidate for treatment of patients with DMD. April 25, 2017